Home/Pipeline/STX-001

STX-001

Obesity

PreclinicalActive

Key Facts

Indication

Obesity

Phase

Preclinical

Status

Active

Company

Supercede Therapeutics

About Supercede Therapeutics

Supercede Therapeutics is a private, preclinical-stage biotech applying an AI/ML-enhanced platform to discover and develop small molecule drugs. Its lead asset, STX-001, is a novel oral ACTRII inhibitor in preclinical development for obesity, aiming to uniquely reduce fat while increasing lean muscle mass. The company is led by founder and CEO Ilan Zipkin, Ph.D., a seasoned biotech investor and entrepreneur, and appears to be in a formative, pre-revenue stage building its initial pipeline and team.

View full company profile

Therapeutic Areas

Metabolic Renal Neurological

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active